ExodusPoint Capital Management LP Invests $1.90 Million in United Therapeutics Co. (NASDAQ:UTHR)

ExodusPoint Capital Management LP bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,383 shares of the biotechnology company's stock, valued at approximately $1,899,000.

A number of other institutional investors have also modified their holdings of the business. HighTower Advisors LLC lifted its position in United Therapeutics by 6.7% during the 3rd quarter. HighTower Advisors LLC now owns 18,050 shares of the biotechnology company's stock worth $6,493,000 after acquiring an additional 1,135 shares during the period. Quantinno Capital Management LP lifted its holdings in shares of United Therapeutics by 32.7% in the 3rd quarter. Quantinno Capital Management LP now owns 1,308 shares of the biotechnology company's stock valued at $469,000 after buying an additional 322 shares during the period. EP Wealth Advisors LLC acquired a new position in shares of United Therapeutics during the 3rd quarter worth $576,000. Orion Portfolio Solutions LLC grew its holdings in United Therapeutics by 60.1% in the third quarter. Orion Portfolio Solutions LLC now owns 3,286 shares of the biotechnology company's stock valued at $1,178,000 after purchasing an additional 1,233 shares during the last quarter. Finally, MML Investors Services LLC acquired a new position in shares of United Therapeutics during the 3rd quarter worth approximately $245,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Price Performance

Shares of NASDAQ UTHR traded up $1.09 during mid-day trading on Monday, hitting $282.25. The company had a trading volume of 42,992 shares, compared to its average volume of 451,817. The stock has a market cap of $12.68 billion, a price-to-earnings ratio of 12.40, a PEG ratio of 0.97 and a beta of 0.63. The firm's 50 day simple moving average is $323.22 and its two-hundred day simple moving average is $351.09. United Therapeutics Co. has a 12 month low of $230.39 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. During the same quarter in the prior year, the firm earned $4.36 earnings per share. Equities analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of analyst reports. StockNews.com lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. HC Wainwright restated a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. Finally, UBS Group boosted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, United Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $388.25.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $370.71, for a total transaction of $3,707,100.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $955,319.67. The trade was a 79.51 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Raymond Dwek sold 4,000 shares of the company's stock in a transaction on Monday, April 7th. The shares were sold at an average price of $284.55, for a total value of $1,138,200.00. Following the completion of the sale, the director now owns 1,750 shares of the company's stock, valued at approximately $497,962.50. This trade represents a 69.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 77,500 shares of company stock valued at $26,994,480 in the last three months. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.